The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15455 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Hongxin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Bispecific. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Fund of Shandong Medical Association-Qilu Special Project, Beijing Science and Technology Innovation Medical Development Foundation.
Abstract (Originalsprache)
Background
For patients with advanced non‐small cell lung cancer (NSCLC) who have received frontline immunochemotherapy, subsequent treatment options are limited. As the first dual programmed cell death‐1 (PD‐1)/cytotoxic T lymphocyte‐associated antigen‐4 bispecific antibody approved globally, cadonilimab demonstrated potential antitumor activity in advanced NSCLC patients resistant to anti‐PD‐1/PD‐L1 antibodies.
Methods
We retrospectively collected efficacy and safety data from advanced NSCLC patients treated with cadonilimab‐based regimens in later therapy lines.
Results
A total of 41 advanced NSCLC patients refractory to anti‐PD‐1/PD‐L1 therapy were enrolled. More than half of the patients received cadonilimab‐based regimen as a fourth or later line of treatment. At the data cutoff date, treatment efficacy could be evaluated in 23 patients. One patient (4.3%) achieved partial response, eight patients (34.8%) experienced stable disease, and 14 patients (60.9%) progressed. The objective response rate and disease control rate were 4.3% and 39.1%, respectively. The median progression‐free survival for all evaluated patients was 108.0 days. Due to the short follow‐up period, the median overall survival has not yet been reached. Treatment‐related adverse events (TRAEs) and immune‐related AEs occurred in 63.4% and 22% patients, respectively. The most common TRAEs included gamma‐glutamyl transferase elevation (17.1%), coughing (14.6%), and fatigue (12.2%). Five patients (12.2%) experienced grade ≥3 TRAEs.
Conclusions
In this heavily pretreated cohort of advanced NSCLC patients, cadonilimab‐based regimens showed moderate antitumor efficacy with a generally tolerable and manageable safety profile. However, more evidence is needed to support the administration of cadonilimab in NSCLC patients refractory to previous anti‐PD‐1/PD‐L1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Clinical Trial Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Oncology, Shandong Provincial Third Hospital, Shandong University, Jinan, China.
ORCID-Profile: Wen Zhao, Chunyan Han, Jun Wang, Jisheng Li
Förderung
- National Natural Science Foundation of China
- Clinical Research Fund of Shandong Medical Association-Qilu Special Project
- Beijing Science and Technology Innovation Medical Development Foundation
- Hui Lan Public Welfare Foundation Project
- Natural Science Foundation of Shandong Province
Zitieren
APA
Li, H., Zhao, W., Li, C., Shen, H., Li, M., Wang, C., Han, C., Yi, C., Wang, J., Meng, X., Liu, L., Yu, S., & Li, J. (2024). The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15455
Vancouver
Li H, Zhao W, Li C, Shen H, Li M, Wang C, et al. The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15455
BibTeX
@article{Li2024,
author = {Li, Hongxin and Zhao, Wen and Li, Chengming and Shen, Hongchang and Li, Meiying and Wang, Chengjun and Han, Chunyan and Yi, Cuihua and Wang, Jun and Meng, Xue and Liu, Lian and Yu, Shuwen and Li, Jisheng},
title = {The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15455}
}
EUVIMED